Related Links
MD Virtual University
Educational Web site with CME modules and case studies for clinicians involved in the management and treatment of RLS.
eMedicine.com
Article for the practitioner treating restless legs syndrome
National Institute of Neurological Disorders and Stroke (NINDS)
The NINDS is one of the research institutes within the National Institutes of Health, one of the world's foremost medical research organizations. Its mission is to acquire new knowledge about all facets of brain and nervous system disorders to improve medical treatment. The NINDS has developed for the public a fact sheet on RLS that can be located here.
WE MOVE™ (Worldwide Education & Awareness for Movement Disorders)
The WE MOVE Web site, the Internet's most comprehensive resource for movement disorder information and the hub of movement disorder activities on the Web, provides information on RLS for patients and caregivers.
National Sleep Foundation
The National Sleep Foundation is an independent nonprofit organization dedicated to improving public health and safety by achieving understanding of sleep and sleep disorders, and by supporting sleep-related education, research, and advocacy.
Learn about RLS
Learn about MIRAPEX
Learn more about clinical evaluation when making a diagnosis of Restless Legs Syndrome (RLS)
Learn more about clinical evaluation [link to: 9.1] when making a diagnosis of Restless Legs Syndrome (RLS)
Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. In clinical trials for RLS, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea (16% vs. 5%), headache (16% vs. 15%), fatigue (9% vs. 7%) and somnolence (6% vs. 3%).
Patients and caregivers should be informed that impulse control disorders and compulsive behaviors have been reported in patients taking dopamine agonists, including MIRAPEX.
This information is intended for U.S. residents only. Products discussed herein may have different labeling in different countries.
Please see full Prescribing Information, including patient information.
